Illumina Total Revenue decreased by 5.9% to $1.09B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.8%, from $1.04B to $1.09B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a -1.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.13B | $1.11B | $1.20B | $1.22B | $1.16B | $1.12B | $1.08B | $1.09B | $1.18B | $1.12B | $1.12B | $1.08B | $1.11B | $1.08B | $1.10B | $1.04B | $1.06B | $1.08B | $1.16B | $1.09B |
| QoQ Change | — | -1.6% | +8.2% | +2.0% | -5.0% | -4.0% | -2.9% | +0.4% | +8.2% | -4.8% | +0.3% | -4.1% | +3.3% | -2.9% | +2.2% | -5.7% | +1.7% | +2.4% | +6.9% | -5.9% |
| YoY Change | — | — | — | — | +3.2% | +0.6% | -9.7% | -11.1% | +1.2% | +0.4% | +3.6% | -1.0% | -5.4% | -3.5% | -1.6% | -3.3% | -4.8% | +0.4% | +5.0% | +4.8% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Consumables | $807.00M | $807.00M | $779.00M | $768.00M | $811.00M | $816.00M | $832.00M | $797.00M |
| Service | $185.00M | $166.00M | $166.00M | $161.00M | $147.00M | $157.00M | $169.00M | $174.00M |
| Instruments | $120.00M | $107.00M | $159.00M | $112.00M | $101.00M | $111.00M | $158.00M | $120.00M |
| Total | $1.11B | $1.08B | $1.10B | $1.04B | $1.06B | $1.08B | $1.16B | $1.09B |
Service and other revenue was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q2 '21 | Q3 '21 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|---|
| Core Illumina | $1.13B | $1.11B | $1.10B | $1.06B | $1.09B | $1.08B | $1.10B |
| Total | $1.13B | $1.11B | $1.12B | $1.08B | $1.11B | $1.08B | $1.10B |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Sequencing | $1.02B | $995.00M | $1.00B | $947.00M | $972.00M | $1.00B | $1.07B | $995.00M |
| Microarray | $96.00M | $85.00M | $100.00M | $94.00M | $87.00M | $83.00M | $93.00M | $96.00M |
| Total | $1.11B | $1.08B | $1.10B | $1.04B | $1.06B | $1.08B | $1.16B | $1.09B |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| United States and Canada | — | — | — | — | — | — | — | $590.00M |
| Europe, Middle East, Africa and Latin America | — | — | — | — | — | — | — | $356.00M |
| Asia-Pacific | — | — | — | — | — | — | — | $93.00M |
| Americas | $640.00M | $609.00M | $589.00M | $570.00M | $586.00M | $612.00M | $638.00M | — |
| Asia-Pacific, Middle East and Africa | $108.00M | $105.00M | $109.00M | $106.00M | $100.00M | $111.00M | $112.00M | — |
| Europe | $289.00M | $291.00M | $326.00M | $293.00M | $310.00M | $309.00M | $353.00M | — |
| Total | $1.11B | $1.08B | $1.10B | $1.04B | $1.06B | $1.08B | $1.16B | $1.09B |
Americas, Asia-Pacific, Middle East and Africa, Europe were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.